AACR D3: The ‘Global One-stop Conference’ for Drug Discovery and Development
The inaugural AACR Drug Discovery and Development (AACR D3) meeting will convene experts to reshape the future of oncology...
The inaugural AACR Drug Discovery and Development (AACR D3) meeting will convene experts to reshape the future of oncology...
The staff of Cancer Research Catalyst was pleased to introduce a new feature this year: Editors' Picks, a monthly...
On September 6, 2018, the U.S. Food and Drug Administration (FDA) and the American Association for Cancer Research hosted...
The 41st San Antonio Breast Cancer Symposium, held Dec. 4-8, drew more than 7,500 attendees from more than 90...
One of the most watched areas in the immuno-oncology field is the development of chimeric antigen receptor (CAR) T-cell...
The past two weeks have seen a flurry of U.S. Food and Drug Administration (FDA) approvals of new treatments...
Radiotherapy is a mainstay of cancer treatment. In recent years, improved technology has allowed many cancer patients to receive...
Pancreatic cancer remains a challenging disease to treat, with a five-year survival rate of less than 9 percent, according...
Wen-Yang Lin, PhD, MS, currently a postdoctoral fellow at Stanford University and the recipient of the 2017 AACR-Genentech Fellowship...
Every month, the editors from the eight scientific journals published by the American Association for Cancer Research (AACR) select...
The human microbiome – the collection of bacteria, viruses, fungi, and other microorganisms that live inside and on the...